
1 **Novel cathelicidin antimicrobial peptides from *Paa robertingeri***

2
3
4 **Abstract:** This study aimed to describe two cathelicidins (cathelicidin-PR1 and
5 cathelicidin-PR2) from the skin of *Paa robertingeri* (Anura: Ranidae). The deduced
6 mature peptides cathelicidin-PR1 and cathelicidin-PR2 were composed of 29 and 25
7 residues, respectively. Cathelicidin - PR1 has higher antimicrobial activity it could kill
8 Gram-positive and Gram-negative bacteria, and even some fungal species.
9 Cathelicidin-PR1 exhibited more effective than AMP in antimicrobial activity against
10 *Pseudomonas maltophilia* clinical strain. On the contrary, cathelicidin-PR2 had very
11 weak antimicrobial activity. Furthermore, cathelicidin-PR1 and cathelicidin-PR2
12 exhibited very low hemolytic activity against human erythrocytes and little
13 hemagglutinating activity. The results suggested that the cathelicidin-PR1 might serve
14 as a template for developing novel antibiotics.

15 **KEYWORDS:** antimicrobial activity; antimicrobial peptide; hemagglutinating
16 activity; hemolytic activity; *Paa robertingeri*

17
18 **1. Introduction**

19 Antimicrobial peptide (AMP) is a kind of small-molecule peptides characterized
20 by strong and broad-spectrum bactericidal activity. In the last 30 years, the
21 widespread distribution of AMPs has been discovered, providing insights into the
22 innate defensive systems that permit multicellular organisms to live in harmony with
23 microbes (Zasloff 2002). Cathelicidins and defensins are the two major AMP families
24 in mammals (Zanetti et al. 1995; Zaiou & Gallo 2002). They can defense against a
25 variety of harmful microorganisms. The presence of cathelicidins in hagfish, the
26 oldest jawless craniates, indicates that cathelicidin genes appeared early in
27 phylogenesis (Uzzell et al. 2003; Duřr et al. 2006; Wang et al. 2008), which
28 illustrates their importance role. Almost 100 kinds of cathelicidins were searched
29 from the Antimicrobial Peptide Database (<http://aps.unmc.edu/AP/main.php>), and the
30 data are constantly updated.

31 Since the discovery of the first cathelicidin (Bac5) from the cDNA of the bovine
32 neutrophils (Zanetti et al. 1993), a variety of new cathelicidins have been found in
33 most of the vertebrates, ranging from mammals, birds, reptiles, amphibians to
34 fishes (Hao et al. 2012; Wei et al. 2013). Cathelicidins possess a conserved structure.
35 Upon activation, most of cathelicidin precursors are proteolytically cleaved to release
36 the C-terminal mature peptide domain (Kopitar et al. 1989; Zanetti et al. 2000; Du`rr
37 et al. 2006; Wang et al. 2008). On the basis of the protein secondary structure,
38 cathelicidins can be divided into four categories: α -helix cathelicidins,
39 extension-spiral cathelicidins, cyclic cathelicidins, and β -sheet cathelicidins.
40 Cathelicidins derived from mammals are mostly α -helical, and the primary structure
41 generally contains 23–40 amino acids (Turner et al. 1998; Tack et al. 2002). Most of
42 the cathelicidins antibacterial peptides are the α -helical structure (Ling et al. 2014).
43 β -sheet cathelicidins generally contain 16–18 amino acids, which are folded into a
44 hairpin structure stabilized by disulfide bonds (Guang et al. 2012).

45 A know mechanism of action of amphibian antimicrobial peptides is that the
46 positively charged polypeptides interact with the microbial cell membrane and induce
47 changes in the membrane structure, resulting in the cytoplasm outflow and eventually
48 causing microbial death (Hancock & Scott 2000). However, evidence shows that the
49 cell membrane is not the only target of antimicrobial peptides. They also act on other
50 parts of microorganisms, such as intracellular DNA and RNA, thereby interfering
51 with microbial metabolic pathways (Hancock 2001).

52 The amphibians face the challenge of adapting to moist environments. Their
53 skins secrete a large volume and variety of antimicrobial peptides. Also, amphibians
54 lack lymphocytes. Hence, secretion of mucous substances is particularly important in
55 such an environment (Lai et al. 2004). In this study, two cathelicidins were identified
56 and characterized from *Paa robertingeri*.

57 **2 Experimental**

58 **2.1 tissue preparation**

59 An adult specimen of *Paa robertingeri* was captured from Fanjingshan in

60 Guizhou province (108°45'55"–108°48'30"E; 27°49'50"–28°1'30"N). A 1- cm² piece
61 of dorsal skin was removed from its back immediately and stored in liquid RNA
62 protector (sample protector for RNA/DNA, TaKaRa, Japan) until use. After collection,
63 this frog was sterilized with alcohol and then set free in its natural habitat. All animal
64 experimental protocols were approved by the Animal Care and Use Ethics Committee
65 of Guizhou Normal University.

66 **2.2 cDNA Library construction and screening of the skin cDNAs encoding** 67 **cathelicidins**

68 The stored skin was washed in water and then ground into powder in liquid
69 nitrogen. The total RNA was extracted using TriZol reagent (Life Technologies, CA,
70 USA). Then, the total RNA was used to construct the cDNA library using the Creator
71 Smart cDNA Library Construction Kit (Clontech, CA, USA). First-strand cDNA
72 synthesis was performed using SMARTScribe Reverse Transcriptase (Clontech) and
73 SMARTer V Oligonucleotide and 3' IF SMARTer CDS Primer. Second-strand cDNA
74 synthesis was performed by a long-distance polymerase chain reaction (PCR) method
75 using Advantage 2 Polymerase Mix (Clontech) in the presence of 5' PCR Primer II A
76 and 3' IF SMARTer PCR Primer. The synthesized cDNA was used as template for the
77 following PCR to screen the cDNAs encoding the cathelicidin peptides.

78 On the basis of the conserved signal peptide domain of previously characterized
79 host defense peptide (HDP) from ranid frogs, a sense oligonucleotide primer
80 (5'-CCCCATGTTACCTTGAAG-3') was designed and coupled with 3' antisense
81 primer (5'-TACGCGACGCGATACGCGAAT-3') according to the sequence of 3' IF
82 SMARTer CDS primer to screen the HDP encoded cDNAs. The PCR procedure was
83 as follows: 5 min of denaturation at 94°C; 30 cycles: denaturation at 94°C for 30 s,
84 primer annealing at °C for 30 s, and extension at 72°C for 1 min. The PCR product
85 was purified by gel electrophoresis and cloned into pMD19-T vector (TaKaRa, Japan)
86 for sequencing.

87 **2.3 Alignment of amphibian cathelicidins**

88 Sequencing results used the National Center for Biotechnology Information (NCBI)
89 Basic Local Alignment Search Tool to remove the carrier and identify the fragment.

90 Then the fragment sequences were translated into amino acids by ExPASy
91 (<http://www.expasy.org/>). The sequences were input into NCBI database, the complete
92 gene sequence encoding cathelicidins of *P. robertingeri* was identified, and the amino
93 acid sequence of the mature peptide was predicted according to the characterized
94 cathelicidins.

95 **2.4 Peptide synthesis**

96 Cathelicidin-PR1 and -PR2 were synthesized by GL Biochem Ltd. (Shanghai,
97 China) and analyzed by high-performance liquid chromatography and mass
98 spectrometry to ensure a purity of more than 95%.

99 **2.5 Antimicrobial assay**

100 Seven strains of standard and clinically isolated microorganisms, including
101 Gram-positive bacteria, Gram-negative bacteria, and fungi, were used in the
102 antimicrobial assay. Minimal inhibitory concentrations (MICs) of the peptides were
103 determined by a standard twofold microdilution method in a 96-well microtiter plate,
104 as described previously (Lu et al. 2010). Briefly, the microorganisms were incubated
105 in Mueller–Hinton broth (MH) at 37°C to exponential phase and diluted with fresh
106 MH broth to 10⁶ colony-forming unit (CFU)/mL. Then, 50 µL of serial dilutions of
107 peptides in MH broth were prepared in 96-well microtiter plates and mixed with 50
108 µL of diluted bacterial inoculum. The plates were incubated at 37°C for 18 h, and the
109 minimal concentration at which no visible growth occurred was recorded. The
110 traditional antibiotic ampicillin was used as a positive control, and the assay was
111 conducted in triplicate.

112 **2.6 Bacterial killing kinetics assay**

113 The bacterial killing kinetics of cathelicidin-PR1 against *Bacillus cereus* clinical
114 strain was determined by measuring the changes in the viable bacterial counts after
115 peptide treatment. *B. cereus* clinical strain was incubated in the Luria-Bertani (LB)
116 liquid medium at 35°C and 200 rpm for 10–16 h and diluted to 10⁵ CFU/mL in the
117 fresh LB liquid medium. Cathelicidin-PR1 was added to the bacterial suspension to a
118 final concentration of 5× MIC, and the bacterial suspension was incubated at 37°C for
119 0, 10, 20, 30, 45, 60, 90, and 120 min. At each time point, aliquots (10 µL) were

120 removed and diluted with fresh LB broth 100 times. Next, 100 μ L of the dilutions
121 were coated on the LB solid medium and incubated for 10–16 h at 37°C. The viable
122 colonies were counted. Ampicillin was used as positive control, and sterile deionized
123 water was used as negative control, the assay was conducted in triplicate at least and
124 took the average.

125 **2.7 Hemolytic assay**

126 Fresh human erythrocytes were collected, mixed in 5 mL of mixing Alsever's
127 solution (8.0 g sodium citrate, 0.55 g citric acid, 20.5 g glucose, and 4.2 g NaCl in 1 L
128 deionized H₂O, pH 6.1) at a volume ratio of 1:1, and centrifuged at 1000 rpm for 5
129 min. The supernatant was removed, washed with 0.9% saline three or four times, and
130 resuspended to a final concentration of 2% (v/v). Serial dilutions of cathelicidin-PR1
131 and cathelicidin-PR2 were incubated with the erythrocyte solutions at 37°C for 30 min,
132 and then the cells were centrifuged at 1500 rpm for 10 min. The supernatant was
133 collected, and the absorbance at 540 nm was measured. The assay was conducted in
134 triplicate. 1% Triton X-100 (v/v) was used as positive control, and 0.9% saline was
135 used as negative control. The assay was conducted in triplicate at least. Percentage of
136 hemolysis ($I\%$) was calculated according to the following formula:

$$137 \quad I\% = (A_{\text{sample}} - A_{\text{negative control}}) / (A_{\text{positive control}} - A_{\text{negative control}}) \times 100\%$$

138 **2.8 Anti-oxidant assay**

139 2,2-Diphenyl-1-picrylhydrazyl (DPPH) is a stable aliphatic nitrogen-centered
140 radical. It can be used to detect the anti-oxidant activity of antimicrobial peptides by
141 radical scavenging assay. DPPH (Sigma, USA) was dissolved in methanol to a final
142 concentration of 6×10^{-5} M. Next, 192 μ L of DPPH solutions were mixed with 8 μ L of
143 serial concentrations of peptide solutions. The mixture was incubated in the dark at
144 room temperature for 30 min, and the amount of reduced DPPH was quantified by
145 measuring a decrease in absorbance at 517 nm. Deionized water was used as negative
146 control. Inhibition of free radicals by DPPH in percentage ($I\%$) was calculated
147 according to the formula:

$$148 \quad I\% = (A_{\text{blank}} - A_{\text{sample}}) / A_{\text{blank}} \times 100\%$$

149

150 **2.9 Erythrocyte hemagglutination assay**

151 Lectins are glycan-binding proteins that can specifically recognize glycan
152 structures and have been identified from a wide variety of organisms (Fujii et al.
153 2012). Fresh human erythrocytes were collected and stored in Alsever's solution to
154 prevent coagulation. The assay was performed in U-well microtiter plates (96 wells)
155 according to the method described by Li et al (2008). The erythrocytes were washed
156 twice with Tris buffered saline (TBS) buffer (6.06 g Tris base and 5.84 g NaCl in 1 L
157 of H₂O, pH 7.5) and TBS + Ca²⁺ buffer (6.06 g Tris base, 5.84 g NaCl, and 1.12 g
158 CaCl₂ in 1 L of H₂O, pH 7.5), centrifuged at 1000 rpm for 5 min, and resuspended in
159 the same buffer to a final concentration of 2% (v/v). Then, 10 µL of peptide solutions
160 (2 mg/mL) were mixed with 90 µL of erythrocyte solutions in a U-well microtiter
161 plate. The plate was incubated at room temperature for 45 min, and the result was
162 observed. Deionized water was used as negative control, and the assay was conducted
163 in triplicate.

164 **2.10 Bioinformatics analysis and structure prediction**

165 The physical and chemical parameters of cathelicidin-PR1 and cathelicidin-PR2
166 were determined by the ProtParam tool (<http://web.expasy.org/protparam/>) through
167 ExPASy Bioinformatics Resource. The secondary structure was predicted using the
168 PSIPRED protein structure prediction server provided by Bioinformatics Group of
169 UCL Department of Computer Science (<http://bioinf.cs.ucl.ac.uk/psipred/>).

170 **2.11 Circular dichroism analysis/spectroscopy**

171 The samples were prepared by dissolving the peptide powder in 60mM sodium
172 dodecyl sulfate (SDS)/H₂O solutions to a concentration of 0.5 mg/mL. The spectra
173 were measured at 298 K (25°C) between 192 and 250 nm using a 0.1-cm path length
174 cell with 1-nm bandwidth, 1-s response time, and a scan speed of 100 nm/min. Three
175 consecutive scans per sample were performed and averaged, followed by subtraction
176 of the solvent signal.

177

178

179

180 **3 Results and discussion**

181 **3.1 Identification and characterization of *P. robertingeri* cathelicidins**

182 Total RNA was extracted from the skin of *P. robertingeri*, and cDNA library
183 was constructed using a cDNA library construction kit. Two cDNAs encoding two
184 different cathelicidins were obtained from the cDNA library by the PCR-based cDNA
185 cloning method. The complete nucleotide sequences and translated amino acid
186 sequences of the two cathelicidin precursors are shown in Figure 1. The cDNAs
187 encoding cathelicidin-PR1 and cathelicidin-PR2 precursors were composed of 587 bp
188 and 607 bp, respectively. The translated protein precursors comprised 147 and 145
189 amino acid residues, respectively. Consistent with other cathelicidins, precursors of
190 cathelicidin-PR1 and cathelicidin-PR2 possessed a typical signal peptide sequence, a
191 highly conserved cathelin domain, and a cationic C-terminal mature peptide sequence.

192 The mature peptides of cathelicidin-PRs were predicted in this study.
193 Cathelicidin-PR1 was composed of 29 amino acid residues, and the amino acid
194 sequence was RKC�LFCKAKQKLKSLSSVIGTVVHPPRG. In contrast,
195 cathelicidin-PR2 was composed of 25 amino acid residues, and the amino acid
196 sequence was KECKDYLCLLMKLGSSSHIESIDP.

197 **3.2 Antimicrobial activity of cathelicidin-PRs**

198 Cathelicidin-PR1 and cathelicidin-PR2 were chemically synthesized and their
199 purity was confirmed to be 95%. The minimal inhibitory concentrations (MICs) of the
200 two peptides against seven microorganisms, including Gram-positive bacteria,
201 Gram-negative bacteria, and fungi, were determined. As listed in Table 1, except for
202 *Acinetobacter baumannii*, cathelicidin-PR1 exhibited potent and broad-spectrum
203 antimicrobial activity against most in the tested clinical strain. Cathelicidin-PR1 is
204 more effective than AMP in antimicrobial activity against *Pseudomonas maltophilia*
205 clinical strain. Unlike cathelicidin-PR1, cathelicidin-PR2 exhibited very weak
206 antimicrobial activity.

207

cathelicidin-PR1

gtgtgctatggatctccgctctcacgttgaggcggctcgctctcagttccggatcaggaa 62
V L W I S A L T L Q A A R S Q S P D Q E 20
gaatgggtcagagaggccttggatctctacaaccagaggaagatggagagttcttctt 122
E W V R E A L D L Y N Q R E D G E F F F 40
aagttcctgtctgatctcccggacgccctcctggaggaggaggaggactctccagcc 182
K F L S D L P D A L L E E E E G D S P A 60
atcggcttcctaatacaaggagacggaatgccccaaatccgaagactcgcacttggagaaa 242
I G F L I K E T E C P K S E D C D L E K 80
tgcgactacaggaaggacggggaggtgaaggtctgctctgtaccgggaggaagaggac 302
C D Y R K D G E V K V C A L Y R E E E D 100
gtgaagtgcgtcagttctccgagaattcacgcgccggggccagcaacaagcgggaag 362
V K C V S L S E N S R A R R A S N K R K 120
tgtaactgttctgcaaaagcgaagcagaagctgaaatctctgagctccgtcatcgggacg 422
C N L F C K A K Q K L K S L S S V I G T 140
gtcgttcatccacctcagggatgaacggcatttctgctgctgcccggcgcaaaaagaacg 482
V V H P P R G - 147
cggcggcagcggcaccgcaacgcttctcgcacggggcaactatcactgcgcttccaa 542
atccagaataatcaataaaccttcataaatccttcgtatatgat 587

cathelicidin-PR2

gtgtgctatggatctccgctctcacattgaggcggctcgctctcagttccggatcaggaa 62
V L W I S A L T L Q A A R S Q S P D Q E 20
gaatgggtcagagaggccttggatctctacaaccagaggaagatggagagtgcttctt 122
E W V R E A L D L Y N Q R E D G E C F F 40
aaattcctgtctgatctcccggacgccctcctggaggaggaaaacgatccgacaatcag 182
K F L S D L P D A L L E E E N D P T I T 60
ttcttaataaaggagacggaatgcctgaaatctgaagatacaacttggaggaaatgtgac 242
F L I K E T E C L K S E D I N L E E C D 80
tacaagaaggacggggaggtgaaggtctgctgaggtaccgggaggagggggagaccatg 302
Y K K D G E V K V C G W Y P E E G E T M 100
aagactctgaaatgtgtcagcctgaccaagaattttcgcgccaagcagaccaccagtaaa 362
K T L K C V S L T K N F R A K R A T S K 120
aaagagtgcaagattatttgtgtaaactgcttatgaaacttggatcctccagccacatc 422
K E C K D Y L C K L L M K L G S S S H I 140
gaaagcatcgatccctgaccatcgcaaggcgtcagcagtaacgcacgcttggaggggca 482
E S I D P - 145
ttccaccgaaacttcttgtacctccttggcagatacagcgttatgttccgctacaa 542
ttcagctgaaagtctgtacattgtatcacatgacgcaatacaattaagccttgggct 602
cagaa 607

208

209 Figure 1. cDNA sequences encoding cathelicidin-PR1 and the predicted prepropeptide
210 sequences. The putative mature peptides of cathelicidin-PRs are boxed and shaded

Table 1. Antimicrobial activity of cathelicidin-PR1 and cathelicidin-PR2

Microorganisms	Minimal Inhibitory Concentrations ($\mu\text{g/ml}$)		
	Cathelicidin-PR1	Cathelicidin-PR2	Amp
<i>Acinetobacter baumannii</i> clinical strain	>100	>100	4.69
<i>Pseudomonas maltophilia</i> clinical strain	75	>100	>100
<i>Staphylococcus aureus</i> clinical strain	37.5	>100	<0.10
<i>Bacillus cereus</i> clinical strain	37.5	>100	4.69
<i>Bacillus subtilis</i> clinical strain	37.5	>100	4.69
<i>Candida albicans</i> clinical strain	37.5	>100	4.69
<i>Candida glabrata</i> clinical strain	37.5	>100	4.69

3.3 Bacterial killing kinetics of cathelicidin-PR1

Using ampicillin as positive control, the killing kinetics of cathelicidin-PR1 against *Bacillus cereus* clinical strain was investigated by a colony counting method. As illustrated in Table 2, at a concentration of $5\times$ MIC, cathelicidin-PR1 rapidly exerted its antimicrobial function. It just took 45 min for cathelicidin-PR1 to kill all the *B. cereus* clinical strain cells. More importantly, the colony forming units (CFUs) remained zero when the incubation time was extended to 120 min, implying that the antimicrobial property of cathelicidin-PR1 was lethal. In contrast, at the same concentration of $5\times$ MIC, it took at least 90 min for the positive control ampicillin to completely kill the *B. cereus* clinical strain cells.

It indicated that cathelicidin-PR1 could rapidly and efficiently kill *B. cereus* clinical strain cells. Therefore, cathelicidin-PR1 might be used as a potential antibiotic.

Table 2 Bacterial killing kinetics of cathelicidin PR1 against *Bacillus cereus* clinical strain

Time	Colony Forming Units (CFUs)							
	0min	10min	20min	30min	45min	1h	1.5h	2h
cathelicidin-PR1	$49.33 \pm$	51 ± 8.19	$41 \pm$	$14.33 \pm$	0 ± 0.00	0 ± 0.00	0 ± 0.00	0 ± 0.00
($5\times$ MIC)	12.06		3.00	7.02				

Ampicillin	37.67 ± 6.11	31.33 ± 11.15	26.67 ± 11.02	15.67 ± 2.52	7.00 ± 2.65	1.33 ± 2.31	0.33 ± 0.58	0 ± 0.00
(5xMIC)								
Blank control	39.67 ± 10.07	32.33 ± 7.57	26.33 ± 3.06	55 ± 9.64	95.67 ± 20.21	98.33 ± 14.57	132.33 ± 15.37	219.67 ± 11.15
(sterile water)								

Note: 5xMIC is 5 times of the minimum inhibitory concentration; cathelicidin-PR1 concentration is 187.5ug/ml; ampicillin concentration is 23.45ug/ml; the results are the average value of three independent repeated experiments (M ± SD).

3.4 Hemolytic and anti-oxidant activity

Cathelicidin-PR1 did not show any hemolytic activity. At a concentration of 200 µg/mL, the rate of hemolysis of cathelicidin-PR1 and cathelicidin-PR2 was 1.78% and 2.01%, respectively. However, at a concentration of 100 µg/mL, the rate of hemolysis of cathelicidin-PRs was 3.87% and 1.12%, respectively (Table 3).

Table 3. Physical and chemical parameters of cathelicidin-PR1 and cathelicidin-PR2

Peptide	Number of amino acids	Molecular weight (Da)	Net charge	Theoretical pI	Grand average of hydropathicity (GRAVY)
Cathelicidin-PR1	29	3195.88	+7	10.59	-0.226
Cathelicidin-PR2	25	2838.34	0	6.74	-0.328

At a concentration of 80 µg/mL, cathelicidin-PR1 and cathelicidin-PR2 showed slight DPPH radical scavenging activity, with % values of 2.92% and 2.30%, respectively.

3.5 Erythrocyte hemagglutinating activity

In this study, cathelicidin-PR1 did not show any hemagglutinating activity irrespective of the presence of Ca²⁺. However, cathelicidin-PR2 showed a weak hemagglutinating activity in the presence of Ca²⁺, but it did not show any hemagglutinating activity in the absence of Ca²⁺ (Fig. 2).




Figure2 Erythrocyte hemagglutinating activity of different concentrations of cathelicidin-PRs

3.6 Physical properties analysis and secondary structure prediction

The physical and chemical parameters of the two cathelicidin-PRs were computed by ProtParam (<http://web.expasy.org/protparam/>); they are listed in Table 4. Besides, the secondary structures of the two cathelicidin-PRs were also predicted by the online prediction software from the University College London (UCL) Department of Computer Science (<http://bioinf.cs.ucl.ac.uk/psipred/>). Cathelicidin-PR1 was mainly composed of a helix and random coil (Fig. 3). Cathelicidin-PR2 was similar to cathelicidin-PR1.

Table 4. The hemolysis ratios of cathelicidin-PR1 and cathelicidin-PR2

	Cathelicidin-PR1	Cathelicidin-PR2
100ug/ml	3.87%	1.12%
200ug/ml	1.78%	2.01%




Figure3 Secondary structure prediction of cathelicidin-PRs.

Circular dichroism analysis is shown in Figure 4. Both cathelicidin-PR1 and cathelicidin-PR2 had random coil configuration in sterile deionized water, while in 60mM sodium dodecyl sulfate (SDS) solvent, they had helix configuration, as predicted.




Figure4 Circular dichroism analysis of cathelicidin-PRs in ultrapure water (a) and SDS (60mM, b) solvent.

4 conclusions

Recent studies have shown that cathelicidins act by interacting with the cell membrane of pathogenic microorganisms, leading to the formation of holes in the cell membrane, leakage of cell contents, and hence killing of pathogens (Wei et al. 2015). Not every cathelicidin has antimicrobial activity (Guang et al. 2012; Ma et al. 2013). This study showed that the charge of cathelicidin-PR1 was +7, while the cathelicidin-PR2 net charge was 0, and the cathelicidin-PR2 no antibacterial activity. It suggested that the antibacterial activity of cathelicidins was related to not only its α -helix structure, but also its charge number. Cathelicidins have potential clinical and agricultural value. At present, Cathelicidin PR1 and cathelicidin PR2 genes were tandem ligated and successfully expressed in *E. coli* BL21 by prokaryotic expression (Deng *et al.*, 2017).

Bacillus cereus can cause human food poisoning, causing symptoms such as nausea, vomiting and abdominal pain. Cathelicidin PR1 has higher antimicrobial activity than ampicillin on the kill *B. cereus*, and also cathelicidin-PR1 has broad-spectrum antimicrobial activity. This indicates that Cathelicidin-PR1 is an important resource for the development of new anti-infection drugs, especially some strains that are resistant to traditional antibiotics.

Conflict of interest

The authors declare that they have no competing interests.

References

- Deng HQ, Chen C, Xiao N, Zhou J. 2017. Prokaryotic Expression of Antimicrobial Peptide CATH PR1–2 from the Skin of *Paa robertingeri* in *Escherichia coli*. Asian Herpetological Research. 8(4): 275-283.
- Du`rr UHN, Sudheendra US, Ramamoorthy A. 2006. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758:1408-1425.

-
- Fujii Y, Dohmae N, Takio K, Kawsar SMA, Matsumoto R, et al. 2012. A lectin from the mussel *Mytilus galloprovincialis* has a highly novel primary structure and induces glycan-mediated cytotoxicity of globotriaosylceramide expressing lymphoma cells. *J Biol Chem* 287: 44772-44783
- Li J, Wu H, Hong J, Xu X, Yang H, et al. 2008. Odorranalectin is a small peptide lectin with potential for drug delivery and targeting, *PLoS ONE* 3:e2381.
- Lu Z, Zhai L, Wang H, Che Q, Wang D, et al. 2010. Novel families of antimicrobial peptides with multiple functions from skin of Xizang plateau frog, *Nanorana parkeri*, *Biochimie* 92:475-481.
- Guang H, Li Z, Wang Y, Lai R, Yu H. 2012. Progress in cathelicidins antimicrobial peptides research, *Zoological Research* 33:523-526
- Hancock REW. 2001. Cationic Peptides: effectors in innate immunity and novel antimicrobials, *The Lancet Infectious Diseases* 1:156-164.
- Hancock REW, Scott MG. 2000. The role of antimicrobial peptides in animal defense. *Proc. Natl. Acad. Sci*, 97(16):8856-8861.
- Hao X, Yang H, Wei L, Lai R. 2012. Amphibian cathelicindin fills the evolutionary gap of cathelicidin in vertebrate. *Amino Acids* 43:677-685
- Kopitar M, Ritonja A, Popovic T, Gabrijelcic D, Krizaj I, Turk V. 1989. Primary structure of a new cysteine proteinase inhibitor from pig leukocytes, *FEBS Lett* 255:211-214
- Lai R, Liang J, Zhang Y. 2004. Antimicrobial peptides in amphibian skins and their application, *Zoological Research* 25:456-468
- Li J, Wu H, Hong J, Xu X, Yang H, Wu B, Wang Y, Zhu J, Lai R, Jiang X, Lin D, Prescott MC, Rees HH. 2008b. Odorranalectin is a small peptide lectin with potential for drug delivery and targeting, *PLoS ONE* 3:e2381
- Ling GY, Gao JX, Zhang SM, Xie ZP, Wei L, Yu HY, Wang YP. 2014. Cathelicidins from the Bullfrog *Rana catesbeiana* provides novel template for peptide antibiotic design. *PLoS ONE* 9(3): e93216.
- Lu Z, Zhai L, Wang H, Che Q, Wang D, Feng F, Zhao Z, Yu H. 2010. Novel families of antimicrobial peptides with multiple functions from skin of Xizang plateau

-
- frog, *Nanorana parkeri*, *Biochimie* 92:475-481
- Ma QQ, Jiao WJ, Wang ZY, Wu CX, Shan AS, Wang YB, Cai J. 2013. Tissue specificity and species superiority of cathelicidin gene expression in Chinese indigenous Min pigs. *Livestock Science* 161:36-40.
- Tack BF, Sawai MV, Kearney WR, Robertson AD, Sherman MA, Wang W, Hong T, Boo LM, Wu HY, Waring AJ, Lehrer RI. 2002. SMAP - 29 has two LPS - binding sites and a central hinge. *Eur J Biochem* 269:1181-1189
- Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. *Antimicrob Agents Chemother* 42: 2206-2214.
- Uzzell T, Stolzenberg ED, Shinnar AE, Zasloff M. 2003. Hagfish intestinal antimicrobial peptides are ancient cathelicidins. *Peptides* 24:1655-1667.
- Wang Y, Hong J, Liu X, Yang H, Liu R, Wu J, Wang A, Lin D, Lai R. 2008. Snake Cathelicidin from *Bungarus fasciatus* is a potent peptide antibiotics. *PLoS ONE* 3:e3217
- Wei L, Gao J, Zhang S, Wu S, Xie Z, Ling G, Kuang Y, Yang Y, Yu H, Wang Y. 2015. Identification and characterization of the first Cathelicidin from sea snakes with potent antimicrobial and anti-inflammatory activity, and special mechanism. *Journal of Biological Chemistry* 290:1633-1652
- Wei L, Yang JJ, He XQ, Mo GX, Hong J, Yan XW, Lin DH, Lai R. 2013. Structure and function of a potent lipopolysaccharide-binding antimicrobial and anti-inflammatory peptide. *Journal of Medicinal Chemistry* 56:3546-3556
- Zaiou M, Gallo RL. 2002. Cathelicidins, essential gene-encoded mammalian antibiotics. *J Mol Med* 80:549-561
- Zanetti M, Del SG, Storici P, Schneider C, Romeo D. 1993. The cDNA of the neutrophil antibiotic Bac5 predicts a pro-sequence homologous to a cysteine proteinase inhibitor that is common to other neutrophil antibiotic., *J Biol Chem* 268:522-526
- Zanetti M, Gennaro R, Romeo D. 1995. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. *FEBS Letters*

374:1-5

Zanetti M, Gennaro R, Scocchi M, Skerlavaj B. 2000. Structure and biology of cathelicidins, *The Biology and Pathology of Innate Immunity Mechanisms* 479:203-218

Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. *Nature* 415:389-395.

UNDER PEER REVIEW